Press Releases
Explore our latest media coverage, press releases, and industry insights. Stay up-to-date with our journey as we continue to innovate and make an impact.
SDK Therapeutics AnnouncesPoster Presentation of Oral Arsenic Trioxide at the 67thAmerican Society of Hematology (ASH) Annual Meeting
SDK Therapeutics Announces Poster Presentation of Oral Arsenic Trioxide at the 67th …
SDK Therapeutics Announces Completion of Enrollment in the Pharmacokinetic Trial of SDK001 (Oral Solution of Arsenic Trioxide) in Patients with Acute Promyelocytic Leukemia
SDK Therapeutics Announces Completion of Enrollment in the Pharmacokinetic Trial of SDK001 …
SDK Therapeutics Announces FDA Orphan Drug Designation Granted to SDK001 (Oral Solution of Arsenic Trioxide) for Treatment of Acute Promyelocytic Leukemia
The FDA Office of Orphan Products Development has granted SDK001 (oral solution …
SDK Therapeutics Acquires Exclusive Right to Develop and Commercialize Arsenic Trioxide Oral Solution for North America and Europe
Biotechnology company focused on developing and commercializing medicines in hematology, oncology, and …